Home > Financial Ratios > VENUS REMEDIES

VENUS REMEDIES
Core EBITDA Margin

    Back to All Ratios
COMMUNITY POLL
for VENUS REMEDIES
Please provide your vote to see the results

VENUS REMEDIES Last 5 Year Core EBITDA Margin History

[Consolidated]

Mar2025Mar2024Mar2023Mar2022Mar2021
   Core EBITDA Margin(%) 9.819.9110.8110.359.81

What is the latest Core EBITDA Margin ratio of VENUS REMEDIES ?

The latest Core EBITDA Margin ratio of VENUS REMEDIES is 9.81 based on Mar2025 Consolidated results.
Year Core EBITDA Margin
Mar20259.81
Mar20249.91
Mar202310.81
Mar202210.35
Mar20219.81

How is Core EBITDA Margin of VENUS REMEDIES Trending?

Years Core EBITDA Margin % Change
Mar2025 9.81
-1.01
Mar2024 9.91
-8.33
Mar2023 10.81
4.44
Mar2022 10.35
5.50
Mar2021 9.81 -

Other Financial Ratios of VENUS REMEDIES


Compare Core EBITDA Margin ratio of peers of VENUS REMEDIES

Peers & Returns Market Capitalization 1 Week 1 Month 1 Year
VENUS REMEDIES ₹655.2 Cr -5.9% 5% 24.5% Stock Analytics
SUN PHARMACEUTICAL INDUSTRIES ₹380,702.0 Cr -3.3% -4.6% -7.9% Stock Analytics
DIVIS LABORATORIES ₹156,908.0 Cr -9% -13.6% 24% Stock Analytics
TORRENT PHARMACEUTICALS ₹120,896.0 Cr -1.1% 7% 8.2% Stock Analytics
CIPLA ₹119,988.0 Cr -2% 0.6% -4% Stock Analytics
DR REDDYS LABORATORIES ₹101,122.0 Cr -1.1% -3.8% -13.3% Stock Analytics


VENUS REMEDIES Share Price vs Sensex


Share Price Returns(%) 1 Week 1 Month 1 Year
VENUS REMEDIES

-5.9%

5%

24.5%

SENSEX

-0.9%

-4.4%

1.6%


You may also like the below Video Courses